The authors concluded that everolimus-eluting stents were associated with a large and significant reduction in stent thrombosis compared with non-everolimus-eluting stents. Similar effects of less magnitude were found with target vessel revascularisation and myocardial infarction. The authors' conclusions should be interpreted cautiously as they over-simplify the review results (given variation in comparator subgroup results).
Authors' objectives
To evaluate whether everolimus-eluting stents reduce stent thrombosis and other cardiac outcomes compared to other drug-eluting stents.
Searching
MEDLINE, Scopus and The Cochrane Library databases and internet sources were searched without language or date restrictions. Additional searches of conference proceedings were performed. References of relevant reviews were checked for additional studies. Search terms were reported.
Study selection
Randomised controlled trials (RCTs) that compared everolimus-eluting stents with non-everolimus-eluting stents and reported frequency of stent thrombosis were eligible for inclusion. Comparisons that included nonpermanent polymer drug-eluting stents were excluded.
Most patients were male. Mean ages ranged from 62 to 67 years. Where reported, rates of patients with diabetes mellitus ranged from 14% to 100%, complex lesion from 11% to 100% and acute presentation from 21% to 65%. Most common comparators were sirolimus-eluting stents followed by paclitaxel-eluting stents and zotarolimus-eluting stents. Nearly all studies reported using clopidogrel for between six and 12 months. Definitions of outcomes were reported. Studies were published between 2007 and 2011.
Two reviewers selected studies for inclusion.
Assessment of study quality
Risk of bias assessment covered selective reporting, incomplete outcome data, outcome blinding, allocation concealment, sequence generation and other bias.
The authors did not report how many reviewers assessed study quality.
Data extraction
Data on outcomes of interest (stent thrombosis, target vessel revascularisation, myocardial infarction and cardiac death) were extracted to calculate risk ratios (RR) and risk differences (RD) on an intention-to-treat basis. Study authors were contacted in case of missing data.
The authors did not report how many reviewers extracted data.
Methods of synthesis
Pooled risk ratios and absolute risk differences were calculated using a random-effects meta-analysis. Heterogeneity was assessed using Ι² and Cochran's Q. Publication bias was assessed using Egger's and Begg's tests. Sensitivity analyses were conducted to assess the robustness of the findings. The association between baseline risk and outcomes of interest were explored using a meta-regression.
